Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YL-90148 in gout and/or asymptomatic hyperuricemia (Phase II)
CTR20201438Phase 2Completed
- Sponsor
- Yingli Pharma
- Start
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of puliginurad in gout, hyperuricemia, sponsored by Yingli Pharma. Started Aug 2020; status: completed.
02
Drugs
puliginurad
03
Conditions
gouthyperuricemia
Beyond the preview
Go deeper on CTR20201438.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20201438.